Rentschler Biopharma SE, a contract development and manufacturing organization (CDMO) for biopharmaceuticals, said it will further enhance and develop the existing collaboration in Japan with Summit Pharmaceuticals International Corporation (SPI), a wholly owned subsidiary of Sumitomo Corporation. Through the collaboration with SPI, Rentschler Biopharma has secured new contracts with Japanese pharmaceutical companies. SPI and Rentschler Biopharma are working together with Japanese clients to outline projects from early clinical stage up to commercial launch. Japan is one of the largest biopharmaceutical markets in the world and is an important area of growth for Rentschler Biopharma.
 
“Our relationship with SPI has been highly productive and fruitful and we have been impressed by their strong network and extensive experience in contract manufacturing and supply,” said Frank Mathias, chief executive officer, Rentschler Biopharma. “Japanese pharmaceutical companies are playing an important and expanding role in the global healthcare market, and we are delighted to be continuing this productive collaboration as we grow our client base in Japan.”
 
Federico Pollano, senior vice president business development, Rentschler Biopharma, said, “We are pleased to be expanding our business with Japanese pharmaceutical companies who value Rentschler Biopharma for our excellent services, outstanding quality and extensive track-record. We very much look forward to working together with SPI to provide clients with the best possible advice and assistance from the start of clinical trials to commercial launch.”